Midodrine - PharmaKB

Midodrine

Midodrine, Orvaten (midodrine) is a small molecule pharmaceutical. Midodrine was first approved as Proamatine on 1996-09-06. It is used to treat orthostatic hypotension and urinary incontinence in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nervous system diseases	D009422
urogenital diseases	D000091642
cardiovascular diseases	D002318
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Midodrine, Orvaten (discontinued: Midodrine, Proamatine)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Midodrine hydrochloride

Tradename	Company	Number	Date	Products
PROAMATINE	Takeda	N-019815 DISCN	1996-09-06	3 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
midodrine hydrochloride	ANDA	2025-09-08
midodrine hcl	ANDA	2024-05-21
midodrine hydrochloride	ANDA	2025-08-15
proamatine	New Drug Application	2010-05-26

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
orthostatic hypotension	—	D007024	I95.1
urinary incontinence	—	D014549	R32

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C01: Cardiac therapy drugs

— C01C: Cardiac stimulants excl. cardiac glycosides

— C01CA: Adrenergic and dopaminergic cardiac stimulants

— C01CA17: Midodrine

HCPCS

No data

Clinical

Clinical Trials

93 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypotension	D007022	EFO_0005251	I95	3	7	4	11	8	30
Orthostatic hypotension	D007024	—	I95.1	5	5	2	8	3	21
Fibrosis	D005355	—	—	—	5	2	2	11	18
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	4	2	1	11	16
Ascites	D001201	—	R18	—	2	3	1	8	12
Shock	D012769	—	R57.1	—	2	1	4	1	8
Hepatorenal syndrome	D006530	—	K76.7	—	4	2	1	2	7
Syndrome	D013577	—	—	1	1	1	1	2	5
Septic shock	D012772	—	A48.3	—	1	2	2	—	5
Syncope	D013575	—	G90.01	—	—	1	1	3	5

Show 11 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Spinal cord injuries	D013119	EFO_1001919	—	—	4	2	—	1	6
Orthostatic intolerance	D054971	—	—	1	1	1	—	3	5
Blood pressure	D001794	EFO_0004325	—	1	2	1	—	—	3
Liver diseases	D008107	EFO_0001421	K70-K77	—	1	1	—	2	3
Autonomic dysreflexia	D020211	EFO_1001762	G90.4	—	2	1	—	—	2
Cerebrovascular circulation	D002560	—	—	—	2	1	—	—	2
Heart failure	D006333	EFO_0003144	I50	1	2	1	—	—	2

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pure autonomic failure	D054970	—	—	5	1	—	—	1	6
Multiple system atrophy	D019578	—	—	4	1	—	—	1	5
Acute kidney injury	D058186	—	N17	—	1	—	—	3	4
Postural orthostatic tachycardia syndrome	D054972	—	G90.A	1	1	—	—	3	4
Tachycardia	D013610	—	R00.0	1	1	—	—	2	3
Ischemic stroke	D000083242	—	—	—	1	—	—	2	3
Stroke	D020521	EFO_0000712	I63.9	—	1	—	—	2	3
Wounds and injuries	D014947	—	T14.8	—	1	—	—	2	3
Sinus tachycardia	D013616	—	—	1	1	—	—	—	1
Hypertension	D006973	EFO_0000537	I10	—	1	—	—	—	1

Show 5 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Parkinson disease	D010300	EFO_0002508	G20	2	—	—	—	1	3
Healthy volunteers/patients	—	—	—	3	—	—	—	—	3
Shy-drager syndrome	D012791	EFO_1001050	—	1	—	—	—	1	2
Hepatopulmonary syndrome	D020065	EFO_1001346	K76.81	1	—	—	—	—	1
Toxemia	D014115	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acute-on-chronic liver failure	D065290	—	—	—	—	—	—	2	2
End stage liver disease	D058625	EFO_1001311	K72.1	—	—	—	—	2	2
Parkinsonian disorders	D020734	—	G20.C	—	—	—	—	1	1
Hydrothorax	D006876	—	J94.8	—	—	—	—	1	1
Only child	D009863	—	—	—	—	—	—	1	1
Spinal anesthesia	D000775	—	—	—	—	—	—	1	1
Liver failure	D017093	—	K72.9	—	—	—	—	1	1
Portal hypertension	D006975	EFO_0000666	K76.6	—	—	—	—	1	1
Primary dysautonomias	D054969	—	—	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Midodrine
INN	midodrine
Description	Midodrine is an aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine. It has a role as a prodrug, an alpha-adrenergic agonist, a sympathomimetic agent and a vasoconstrictor agent. It is a secondary alcohol, an amino acid amide and an aromatic ether. It is functionally related to a glycinamide and a deglymidodrine. It is a conjugate base of a midodrine(1+).
Classification	Small molecule
Drug class	sympathomimetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	COc1ccc(OC)c(C(O)CNC(=O)CN)c1